215 related articles for article (PubMed ID: 15239150)
1. New drug helps Parkinson's "off" periods.
Health News; 2004 Jul; 10(7):2. PubMed ID: 15239150
[No Abstract] [Full Text] [Related]
2. Drug for "off" episodes of Parkinson's--effective but limited.
Mayo Clin Health Lett; 2005 Jul; 23(7):4. PubMed ID: 16189845
[No Abstract] [Full Text] [Related]
3. New treatment for people with Parkinson's.
FDA Consum; 2004; 38(4):5. PubMed ID: 15346564
[No Abstract] [Full Text] [Related]
4. Apomorphine for the acute treatment of "off" episodes in Parkinson's disease.
Stacy M; Silver D
Parkinsonism Relat Disord; 2008; 14(2):85-92. PubMed ID: 18083605
[TBL] [Abstract][Full Text] [Related]
5. Transdermal apomorphine permeation from microemulsions: a new treatment in Parkinson's disease.
Priano L; Albani G; Brioschi A; Calderoni S; Lopiano L; Rizzone M; Cavalli R; Gasco MR; Scaglione F; Fraschini F; Bergamasco B; Mauro A
Mov Disord; 2004 Aug; 19(8):937-42. PubMed ID: 15300660
[TBL] [Abstract][Full Text] [Related]
6. [Drug treatments and motor complications in advanced stage Parkinson's disease ].
Marion MH
Rev Neurol (Paris); 2000; 156 Suppl 2 Pt 2():160-4. PubMed ID: 10916047
[No Abstract] [Full Text] [Related]
7. Continuous subcutaneous infusion of apomorphine can be used safely in patients with Parkinson's disease and pre-existing visual hallucinations.
van Laar T; Postma AG; Drent M
Parkinsonism Relat Disord; 2010 Jan; 16(1):71-2. PubMed ID: 19524477
[No Abstract] [Full Text] [Related]
8. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.
Chen JJ; Obering C
Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444
[TBL] [Abstract][Full Text] [Related]
9. Future delivery systems for apomorphine in patients with Parkinson's disease.
van Laar T; Van der Geest R; Danhof M
Adv Neurol; 1999; 80():535-44. PubMed ID: 10410768
[No Abstract] [Full Text] [Related]
10. Effects of long-term, continuous subcutaneous apomorphine infusions on motor complications in advanced Parkinson's disease.
Wenning GK; Bösch S; Luginger E; Wagner M; Poewe W
Adv Neurol; 1999; 80():545-8. PubMed ID: 10410769
[No Abstract] [Full Text] [Related]
11. Update on apomorphine for the rapid treatment of hypomobility ("off") episodes in Parkinson's disease.
Obering CD; Chen JJ; Swope DM
Pharmacotherapy; 2006 Jun; 26(6):840-52. PubMed ID: 16716137
[TBL] [Abstract][Full Text] [Related]
12. Levodopa in the treatment of Parkinson's disease: current controversies.
Gerlach M; Reichmann H; Riederer P
Mov Disord; 2005 May; 20(5):643; author reply 643-4. PubMed ID: 15732130
[No Abstract] [Full Text] [Related]
13. Use of apomorphine in Parkinson's disease.
Stocchi F
Neurol Sci; 2008 Dec; 29 Suppl 5():S383-6. PubMed ID: 19381769
[TBL] [Abstract][Full Text] [Related]
14. [Use of apomorphine in Parkinson s disease].
Giménez-Roldán S; García- Muñozguren S
Rev Neurol; 2002 Oct 1-15; 35(7):668-74. PubMed ID: 12389155
[TBL] [Abstract][Full Text] [Related]
15. Apomorphine-induced eosinophilic panniculitis and hypereosinophilia in Parkinson disease.
Pot C; Oppliger R; Castillo V; Coeytaux A; Hauser C; Burkhard PR
Neurology; 2005 Jan; 64(2):392-3. PubMed ID: 15668455
[No Abstract] [Full Text] [Related]
16. The pragmatic use of apomorphine at the end of life.
Dewhurst F; Lee M; Wood B
Palliat Med; 2009 Dec; 23(8):777-9. PubMed ID: 19837701
[TBL] [Abstract][Full Text] [Related]
17. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges.
Katzenschlager R; Hughes A; Evans A; Manson AJ; Hoffman M; Swinn L; Watt H; Bhatia K; Quinn N; Lees AJ
Mov Disord; 2005 Feb; 20(2):151-7. PubMed ID: 15390035
[TBL] [Abstract][Full Text] [Related]
18. Apomorphine in dopaminergic therapy.
Subramony JA
Mol Pharm; 2006; 3(4):380-5. PubMed ID: 16889431
[TBL] [Abstract][Full Text] [Related]
19. Apomorphine. A novel effect for an old compound.
Scarselli M; Armogida M; Pardini C; Chiacchio S; Corsini GU
Adv Neurol; 2001; 86():367-72. PubMed ID: 11553998
[No Abstract] [Full Text] [Related]
20. Subcutaneous apomorphine in patients with advanced Parkinson's disease: a dose-escalation study with randomized, double-blind, placebo-controlled crossover evaluation of a single dose.
Pahwa R; Koller WC; Trosch RM; Sherry JH;
J Neurol Sci; 2007 Jul; 258(1-2):137-43. PubMed ID: 17466338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]